Sunrise Technologies shares slump after FDA panel rejection
This article was originally published in Clinica
The president and CEO of Sunrise Technologies has attempted to correct "inaccurate information" about the company following the FDA panel rejection of its laser hyperopia treatment in July (see Clinica No 868, p 15). The rejection prompted investors in the company to sell massively and critics to question its future survival prospects.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.